Amdizalisib

DB21514InvestigationalSmall molecule

Amdizalisib is a small molecule drug. Amdizalisib is under investigation in clinical trial NCT05713110 (A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma). Amdizalisib has a... Amdizalisib has a monoisotopic molecular weight of 390.11 Da.

Mechanism: Pharmacologically active on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Curator reviewed
Formula / weight: C₁₉H₁₅ClN₈ · 390.84 g/mol (avg)
Code names: HMPL-689

Resolves to

Compound

UNIIF3YMY7783PCAS1894229-05-0ChEMBLCHEMBL4438249ChEBI757670PubChem118981804

Structure

InChIKeyWKDBRCUUDXLTIM-NSHDSACASA-NSMILESC[C@H](NC1=C(C#N)C(N)=NC=N1)C1=CC2=NC=C(Cl)N2N=C1C1=CC=CC=C1

Targets

O00329PIK3CD

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Amdizalisib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account